264 related articles for article (PubMed ID: 34359990)
1. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Alnatsha A; Li Q; Oehrle B; Weiss FU; Sendler M; Distler M; Uhl W; Fahlbusch T; Goni E; Beyer G; Chromik A; Bahra M; Klein F; Pilarsky C; Grützmann R; Lerch MM; Lauber K; Christiansen N; Kamlage B; Regel I; Mayerle J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359990
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
3. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer.
Ohara Y; Liu H; Craig AJ; Yang S; Moreno P; Dorsey TH; Cawley H; Azizian A; Gaedcke J; Ghadimi M; Hanna N; Ambs S; Hussain SP
Int J Cancer; 2024 Aug; 155(3):569-581. PubMed ID: 38630934
[TBL] [Abstract][Full Text] [Related]
4. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification of Genes Associated with Hypoxic Lipid Metabolism in Pancreatic Cancer.
Li Y; Liang X; Che G; Chen Y; Luo L; Liu K; Xie R; Zeng L
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291742
[TBL] [Abstract][Full Text] [Related]
6. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
7. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Daemen A; Peterson D; Sahu N; McCord R; Du X; Liu B; Kowanetz K; Hong R; Moffat J; Gao M; Boudreau A; Mroue R; Corson L; O'Brien T; Qing J; Sampath D; Merchant M; Yauch R; Manning G; Settleman J; Hatzivassiliou G; Evangelista M
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4410-7. PubMed ID: 26216984
[TBL] [Abstract][Full Text] [Related]
8. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Fukuda T; Sumida K; Deguchi Y; Mikata K; Nishioka K; Kawamura S; Uwagawa S; Suzui M; Alexander DB; Tsuda H
Carcinogenesis; 2013 Jun; 34(6):1251-9. PubMed ID: 23393225
[TBL] [Abstract][Full Text] [Related]
10. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
Front Immunol; 2021; 12():719105. PubMed ID: 35111149
[TBL] [Abstract][Full Text] [Related]
11. Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats.
Wen S; Li Z; Feng J; Bai J; Lin X; Huang H
Cancer Sci; 2016 Jun; 107(6):836-45. PubMed ID: 27019331
[TBL] [Abstract][Full Text] [Related]
12. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.
Zhang G; He P; Tan H; Budhu A; Gaedcke J; Ghadimi BM; Ried T; Yfantis HG; Lee DH; Maitra A; Hanna N; Alexander HR; Hussain SP
Clin Cancer Res; 2013 Sep; 19(18):4983-93. PubMed ID: 23918603
[TBL] [Abstract][Full Text] [Related]
13. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
17. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
20. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
